I love seeing more attention for Lenzilumab in Car-T. This seems to get completely overlooked with Covid, but Zuma-19 is on pace to provide Phase-I data in Q-2, and Phase II interim Data in Q-4. Currently active in 10 prestigious Hospitals.
Phase III may not be necessary for approval in ZUMA-19; precedent is CAR-Ts to date have been approved on Phase II data
Original Plans included studies with Novartis Kymriah. Now we also have Bristol Myers Squibb Breyanzi, a CAR-T treatment for diffuse large B-cell lymphoma.